{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:32:35Z","timestamp":1785465155790,"version":"3.56.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Botulinum toxin A (BoNT-A) is widely used in treating dystonia and spasticity to managing chronic migraine and cosmetic applications. However, its immunogenic potential presents challenges, such as the development of neutralizing antibodies that lead to diminished therapeutic efficacy over time, known as secondary nonresponse.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>This review aims to bridge the knowledge gap regarding the immunogenic mechanisms of BoNT-A and to explore effective management strategies to mitigate these immune responses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>The authors conducted a systematic search in databases including PubMed, Embase, and Web of Science, using keywords related to BoNT-A's immunogenicity. The selection process refined 157 initial articles down to 23 relevant studies, which underwent analysis to investigate the underlying mechanisms of immunogenicity and the factors influencing it.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>The analysis revealed that both the neurotoxin component and the neurotoxin-associated proteins could elicit an immune response. However, only antibodies against the core toxin influence therapeutic outcomes. Various patient-specific factors such as genetic predispositions and prior immune experiences, along with treatment-related factors such as dosage and frequency, play crucial roles in shaping these responses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Understanding the specific immunogenic triggers and responses to BoNT-A is critical for optimizing treatment protocols and improving patient outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000004293","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T23:54:38Z","timestamp":1724889278000},"page":"S117-S126","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Immunogenicity of Botulinum Toxin A: Insights"],"prefix":"10.1097","volume":"50","author":[{"given":"Eqram","family":"Rahman","sequence":"first","affiliation":[{"name":"Research and Innovation Hub, Innovation Aesthetics, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean D. A.","family":"Carruthers","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"R1-20241006","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/PRS.0000000000008904","article-title":"Botulinum toxin type A immunogenicity across multiple indications: an overview systematic review","volume":"149","author":"Rahman","year":"2022","journal-title":"Plast Reconstr Surg"},{"key":"R2-20241006","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/asj\/sjab058","article-title":"Immunogenicity to botulinum toxin type A: a systematic review with meta-analysis across therapeutic indications","volume":"42","author":"Rahman","year":"2022","journal-title":"Aesthet Surg J"},{"key":"R3-20241006","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.rehab.2019.03.004","article-title":"Immunogenicity induced by botulinum toxin injections for limb spasticity: a systematic review","volume":"62","author":"Mathevon","year":"2019","journal-title":"Ann Phys Rehabil Med"},{"key":"R4-20241006","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.baga.2017.06.001","article-title":"Systematic analysis of botulinum neurotoxin type A immunogenicity in clinical studies","volume":"9","author":"Lacroix-Desmazes","year":"2017","journal-title":"Basal Ganglia"},{"key":"R5-20241006","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12640-015-9565-5","article-title":"Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis","volume":"29","author":"Fabbri","year":"2016","journal-title":"Neurotox Res"},{"key":"R6-20241006","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.toxicon.2020.11.411","article-title":"Neutralizing antibody conversion with onabotulinumtoxinA from global studies across multiple indications in nearly 30,000 patient records: a meta-analysis","volume":"190","author":"Jankovic","year":"2021","journal-title":"Toxicon"},{"key":"R7-20241006","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/17512433.2020.1772053","article-title":"Immunogenicity-unwanted immune responses to biological drugs\u2013can we predict them?","volume":"14","author":"Matucci","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R8-20241006","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijwd.2016.05.001","article-title":"A dermatologist guide to immunogenicity","volume":"2","author":"Blattner","year":"2016","journal-title":"Int J Womens Dermatol"},{"key":"R9-20241006","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","article-title":"Clinical relevance of botulinum toxin immunogenicity","volume":"26","author":"Benecke","year":"2012","journal-title":"BioDrugs"},{"key":"R10-20241006","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","article-title":"Long-term botulinum toxin efficacy, safety, and immunogenicity","volume":"20","author":"Mejia","year":"2005","journal-title":"Mov Disord"},{"key":"R11-20241006","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/toxins16020101","article-title":"Complexing protein-free botulinum neurotoxin A formulations: implications of excipients for immunogenicity","volume":"16","author":"Martin","year":"2024","journal-title":"Toxins (Basel)."},{"key":"R12-20241006","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/toxins11090491","article-title":"Immunogenicity associated with botulinum toxin treatment","volume":"11","author":"Bellows","year":"2019","journal-title":"Toxins (Basel)."},{"key":"R13-20241006","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J Neural Transm (Vienna)"},{"key":"R14-20241006","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1017\/S1092852900023750","article-title":"Immunogenicity of botulinum toxin therapy","volume":"5","author":"Critchfield","year":"2000","journal-title":"CNS Spectr"},{"key":"R15-20241006","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2147\/CCID.S363321","article-title":"Causes of botulinum toxin treatment failure","volume":"15","author":"Shtefan","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R16-20241006","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1007\/s12325-021-01882-9","article-title":"Immunogenicity of botulinum toxin formulations: potential therapeutic implications","volume":"38","author":"Carr","year":"2021","journal-title":"Adv Ther"},{"key":"R17-20241006","article-title":"Botulinumtoxin type A therapy for blepharospasm(Review)","author":"Costa","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R18-20241006","doi-asserted-by":"crossref","first-page":"e4217","DOI":"10.1097\/GOX.0000000000004217","article-title":"Immunogenicity associated with aesthetic Botulinumtoxin A: a survey of asia-pacific physicians' experiences and recommendations","volume":"10","author":"Park","year":"2022","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R19-20241006","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jocd.12108","article-title":"Clinical resistance to three types of botulinum toxin type A in aesthetic medicine","volume":"13","author":"Stephan","year":"2014","journal-title":"J Cosmet Dermatol"},{"key":"R20-20241006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","article-title":"Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products","volume":"15","author":"Frevert","year":"2015","journal-title":"Drugs R&D"},{"key":"R21-20241006","doi-asserted-by":"crossref","first-page":"e2627","DOI":"10.1097\/GOX.0000000000002627","article-title":"Neurotoxin impurities: a review of threats to efficacy","volume":"8","author":"Park","year":"2020","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R22-20241006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-0035-1571213","article-title":"Botulinum toxin: preparations for clinical use, immunogenicity, side effects, and safety profile","volume":"36","author":"Dashtipour","year":"2016","journal-title":"Semin Neurol"},{"key":"R23-20241006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/toxins15010060","article-title":"Clinical immunogenicity of DaxibotulinumtoxinA for injection in glabellar lines: pooled data from the SAKURA phase 3 trials","volume":"15","author":"Gallagher","year":"2023","journal-title":"Toxins (Basel)"},{"key":"R24-20241006","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cellimm.2015.10.008","article-title":"Engineering less immunogenic and antigenic FVIII proteins","volume":"301","author":"Pratt","year":"2016","journal-title":"Cell Immunol"},{"key":"R25-20241006","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.toxicon.2019.07.005","article-title":"The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT\/A products","volume":"168","author":"Kutschenko","year":"2019","journal-title":"Toxicon"},{"key":"R26-20241006","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.toxicon.2009.01.017","article-title":"Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins","volume":"53","author":"Kukreja","year":"2009","journal-title":"Toxicon"},{"key":"R27-20241006","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/toxins5020249","article-title":"Long-term efficacy and safety of botulinum toxin injections in dystonia","volume":"5","author":"Ramirez-Castaneda","year":"2013","journal-title":"Toxins (Basel)."},{"key":"R28-20241006","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0264-410X(02)00058-0","article-title":"Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"issue":"(Suppl 8)","key":"R29-20241006","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20022","article-title":"Clinical presentation and management of antibody-induced failure of botulinum toxin therapy","volume":"19","author":"Dressler","year":"2004","journal-title":"Mov Disord"},{"key":"R31-20241006","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1524-4725.2011.02087.x","article-title":"Handling botulinum toxins: an updated literature review","volume":"37","author":"Trindade De Almeida","year":"2011","journal-title":"Dermatol Surg"},{"key":"R32-20241006","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/019459989310800205","article-title":"Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage","volume":"108","author":"Gartlan","year":"1993","journal-title":"Otolaryngol-Head Neck Surg"},{"key":"R33-20241006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1020691215056","article-title":"Molecular properties of a hemagglutinin purified from type A Clostridium botulinum","volume":"18","author":"Sharma","year":"1999","journal-title":"J Protein Chem"},{"key":"R34-20241006","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.toxicon.2014.02.004","article-title":"Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells","volume":"82","author":"Wang","year":"2014","journal-title":"Toxicon"},{"key":"R35-20241006","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"R36-20241006","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/sji.12327","article-title":"Antidrug antibodies: B cell immunity against therapy","volume":"82","author":"Fogdell-Hahn","year":"2015","journal-title":"Scand J Immunol"},{"key":"R37-20241006","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/FTD.0b013e318295f6b2","article-title":"Monitoring antigen-specific biologics: current knowledge and future prospects","volume":"35","author":"Zandvliet","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R38-20241006","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1128\/iai.65.5.1626-1630.1997","article-title":"Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms","volume":"65","author":"Chen","year":"1997","journal-title":"Infect Immun"},{"key":"R39-20241006","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jmb.2006.09.084","article-title":"Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display","volume":"365","author":"Levy","year":"2007","journal-title":"J Mol Biol"},{"key":"R40-20241006","doi-asserted-by":"crossref","first-page":"e4924","DOI":"10.1371\/journal.pone.0004924","article-title":"Epitope characterization and variable region sequence of F1-40, a high-affinity monoclonal antibody to botulinum neurotoxin type A (Hall strain)","volume":"4","author":"Scotcher","year":"2009","journal-title":"PLoS One"},{"key":"R41-20241006","doi-asserted-by":"crossref","first-page":"e2005523","DOI":"10.1371\/journal.pbio.2005523","article-title":"Human T SCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness","volume":"16","author":"Costa Del Amo","year":"2018","journal-title":"Plos Biol"},{"key":"R42-20241006","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.4049\/jimmunol.1600973","article-title":"NK cell responses redefine immunological memory","volume":"197","author":"Adams","year":"2016","journal-title":"J Immunol (Baltimore, Md, 1950)"},{"key":"R43-20241006","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/ni.2744","article-title":"The developmental pathway for CD103+ CD8+ tissue-resident memory T cells of skin","volume":"14","author":"MacKay","year":"2013","journal-title":"Nat Immunol"},{"key":"R44-20241006","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00011-020-01320-6","article-title":"Tissue-resident memory T cells in the skin","volume":"69","author":"Khalil","year":"2020","journal-title":"Inflamm Res"},{"key":"R45-20241006","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ana.20098","article-title":"Clinical impact of antibody formation to botulinum toxin A in children","volume":"55","author":"Herrmann","year":"2004","journal-title":"Ann Neurol"},{"key":"R46-20241006","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/08820139.2017.1368544","article-title":"The regions on the light chain of botulinum neurotoxin type A recognized by T cells from toxin-treated cervical dystonia patients. The complete human T-cell recognition map of the toxin molecule","volume":"47","author":"Oshima","year":"2018","journal-title":"Immunol Invest"},{"key":"R47-20241006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.humimm.2008.05.001","article-title":"Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies","volume":"69","author":"Solberg","year":"2008","journal-title":"Hum Immunol"},{"key":"R48-20241006","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1442-2042.2008.02016.x","article-title":"Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure","volume":"15","author":"Schulte-Baukloh","year":"2008","journal-title":"Int J Urol"},{"key":"R49-20241006","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group","volume":"246","author":"Kessler","year":"1999","journal-title":"J Neurol"},{"key":"R50-20241006","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?","volume":"32","author":"Lange","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"R51-20241006","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12640-012-9314-y","article-title":"Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review","volume":"22","author":"Colosimo","year":"2012","journal-title":"Neurotox Res"},{"issue":"Pt 4","key":"R52-20241006","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/brain\/120.4.571","article-title":"Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study","volume":"120","author":"Ceballos-Baumann","year":"1997","journal-title":"Brain a J Neurol"},{"key":"R53-20241006","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/1531-8249(200007)48:1<20::AID-ANA5>3.0.CO;2-U","article-title":"Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia","volume":"48","author":"Gilio","year":"2000","journal-title":"Ann Neurol"},{"key":"R54-20241006","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/00207450600674525","article-title":"Central effect of botulinum toxin type A in humans","volume":"116","author":"Kim","year":"2006","journal-title":"Int J Neurosci"},{"key":"R55-20241006","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/bmj.38906.704549.7C","article-title":"Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial","volume":"333","author":"Diggle","year":"2006","journal-title":"BMJ"},{"key":"R56-20241006","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/ijms20092159","article-title":"Dendritic cell-mediated th2 immunity and immune disorders","volume":"20","author":"Kumar","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R57-20241006","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/asj\/sjad044","article-title":"Microtoxin for improving pore size, skin laxity, sebum control, and scars: a roundtable on integrating intradermal botulinum toxin type A microdoses into clinical practice","volume":"43","author":"Fabi","year":"2023","journal-title":"Aesthet Surg J"},{"key":"R58-20241006","first-page":"22","article-title":"Evaluation of intradermal injection of botulinum toxin A for facial lifting","volume":"13","author":"Atwa","year":"2020","journal-title":"J Clin Aesthet Dermatol"},{"key":"R59-20241006","doi-asserted-by":"crossref","first-page":"458","DOI":"10.5021\/ad.2018.30.4.458","article-title":"Intradermal injection of botulinum toxin: a safer treatment modality for forehead wrinkles","volume":"30","author":"Jun","year":"2018","journal-title":"Ann Dermatol"},{"key":"R60-20241006","first-page":"847","article-title":"Use of intradermal botulinum toxin to reduce sebum production and facial pore size","volume":"7","author":"Shah","year":"2008","journal-title":"J Drugs Dermatol JDD"},{"key":"R61-20241006","doi-asserted-by":"crossref","first-page":"e12433","DOI":"10.1111\/dth.12433","article-title":"The efficacy of intradermal injection of type A botulinum toxin for facial rejuvenation","volume":"30","author":"Zhu","year":"2017","journal-title":"Dermatol Ther"},{"key":"R62-20241006","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/DSS.0000000000002379","article-title":"Are there differences between intradermal and intramuscular injections of botulinum toxin on the forehead?","volume":"46","author":"Kim","year":"2020","journal-title":"Dermatol Surg"},{"key":"R63-20241006","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13555-020-00414-7","article-title":"Intradermal micro-dosing of AbobotulinumtoxinA for face-lifting: how long does it last?","volume":"10","author":"Wanitphakdeedecha","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R64-20241006","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12033-010-9251-z","article-title":"Cell-based assays for high-throughput screening","volume":"45","author":"An","year":"2010","journal-title":"Mol Biotechnol"},{"key":"R65-20241006","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/toxins15050342","article-title":"Neutralizing antibody formation with OnabotulinumtoxinA (BOTOX\u00ae) treatment from global registration studies across multiple indications: a meta-analysis","volume":"15","author":"Jankovic","year":"2023","journal-title":"Toxins (Basel)"},{"issue":"1","key":"R66-20241006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/toxins15010060","article-title":"Immunogenicity of DaxibotulinumtoxinA for injection in glagellar lines: pooled data from the SAKURA phase 3 trials","volume":"15","author":"Gallagher","year":"2023","journal-title":"Toxins (Basel)"},{"issue":"1","key":"R67-20241006","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12640-015-9565-5","article-title":"Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis","volume":"29","author":"Fabbri","year":"2015","journal-title":"Neurotox Res"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T03:16:52Z","timestamp":1728184612000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":66,"journal-issue":{"issue":"9S","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004293","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}